| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 250.9 | 206.0 |
| Gross profit | 152.6 | 119.0 |
| Profit before tax | 10.9 | -9.5 |
| Net income | 8.9 | -9.9 |
| EPS (diluted, $ a share) | $0.26 | $-0.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +21.8% |
|---|---|
| Gross margin | 60.8% |
| Operating margin | 3.2% |
10-Q filed with the SEC, NASDAQ: SLAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Silicon Laboratories Inc.: key numbers
- Share price
- $221.65Close, Nov 16
- Market cap
- $7.4B
- Shares outstanding
- 33.38MLatest SEC cover page
- Sector
- Manufacturing
- Industry
- Semiconductors & Related DevicesSIC 3674
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Silicon Laboratories Inc.
All →Silicon Laboratories Financial Results
Silicon Laboratories reported Q3 2026 revenue of $251 million, a 22% year-over-year increase driven by record medical revenue and broad-based growth in Industrial & Commercial and Home & Life segments. GAAP diluted EPS improved to $0.26 from a loss in the prior year, while non-GAAP EPS rose 228% to $1.05. The company suspended forward-looking guidance due to its pending acquisition by Texas Instruments.
- Term
- Q3 2026
“We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued. Earnings significantly outpaced revenue growth, a result of strong operational execution by the team. Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.”
Matt Johnson, President and Chief Executive Officer